167 related articles for article (PubMed ID: 33799049)
1. Cross-resistance and drug sequence in prostate cancer.
Buck SAJ; Koolen SLW; Mathijssen RHJ; de Wit R; van Soest RJ
Drug Resist Updat; 2021 May; 56():100761. PubMed ID: 33799049
[TBL] [Abstract][Full Text] [Related]
2. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance.
Jamroze A; Chatta G; Tang DG
Cancer Lett; 2021 Oct; 518():1-9. PubMed ID: 34118355
[TBL] [Abstract][Full Text] [Related]
4. Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer.
Lombard AP; Liu L; Cucchiara V; Liu C; Armstrong CM; Zhao R; Yang JC; Lou W; Evans CP; Gao AC
Mol Cancer Ther; 2018 Oct; 17(10):2197-2205. PubMed ID: 29891490
[TBL] [Abstract][Full Text] [Related]
5. Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants.
Shiota M; Dejima T; Yamamoto Y; Takeuchi A; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Kajioka S; Uchiumi T; Eto M
Cancer Sci; 2018 Oct; 109(10):3224-3234. PubMed ID: 30051622
[TBL] [Abstract][Full Text] [Related]
6. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents.
Zhang G; Liu X; Li J; Ledet E; Alvarez X; Qi Y; Fu X; Sartor O; Dong Y; Zhang H
Oncotarget; 2015 Sep; 6(27):23358-71. PubMed ID: 26160840
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor splice variants in the era of enzalutamide and abiraterone.
Nakazawa M; Antonarakis ES; Luo J
Horm Cancer; 2014 Oct; 5(5):265-73. PubMed ID: 25048254
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.
Kahn B; Collazo J; Kyprianou N
Int J Biol Sci; 2014; 10(6):588-95. PubMed ID: 24948871
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor variation affects prostate cancer progression and drug resistance.
McCrea E; Sissung TM; Price DK; Chau CH; Figg WD
Pharmacol Res; 2016 Dec; 114():152-162. PubMed ID: 27725309
[TBL] [Abstract][Full Text] [Related]
11. Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer.
Zhang T; Karsh LI; Nissenblatt MJ; Canfield SE
Clin Genitourin Cancer; 2020 Feb; 18(1):1-10. PubMed ID: 31653572
[TBL] [Abstract][Full Text] [Related]
12. Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens.
Ylitalo EB; Thysell E; Thellenberg-Karlsson C; Lundholm M; Widmark A; Bergh A; Josefsson A; Brattsand M; Wikström P
Prostate; 2020 Feb; 80(2):214-224. PubMed ID: 31799745
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
van Soest RJ; de Morrée ES; Kweldam CF; de Ridder CMA; Wiemer EAC; Mathijssen RHJ; de Wit R; van Weerden WM
Eur Urol; 2015 Jun; 67(6):981-985. PubMed ID: 25484141
[TBL] [Abstract][Full Text] [Related]
14. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
15. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
[TBL] [Abstract][Full Text] [Related]
16. ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.
Lombard AP; Liu C; Armstrong CM; Cucchiara V; Gu X; Lou W; Evans CP; Gao AC
Mol Cancer Ther; 2017 Oct; 16(10):2257-2266. PubMed ID: 28698198
[TBL] [Abstract][Full Text] [Related]
17. Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer.
Graf RP; Hullings M; Barnett ES; Carbone E; Dittamore R; Scher HI
Eur Urol; 2020 Feb; 77(2):170-177. PubMed ID: 31648903
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor plasticity and its implications for prostate cancer therapy.
Snow O; Lallous N; Singh K; Lack N; Rennie P; Cherkasov A
Cancer Treat Rev; 2019 Dec; 81():101871. PubMed ID: 31698174
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.
Efstathiou E; Titus M; Wen S; Hoang A; Karlou M; Ashe R; Tu SM; Aparicio A; Troncoso P; Mohler J; Logothetis CJ
Eur Urol; 2015 Jan; 67(1):53-60. PubMed ID: 24882673
[TBL] [Abstract][Full Text] [Related]
20. The Role of Crosstalk between AR3 and E2F1 in Drug Resistance in Prostate Cancer Cells.
Xu J; Yang X; Deshmukh D; Chen H; Fang S; Qiu Y
Cells; 2020 Apr; 9(5):. PubMed ID: 32354165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]